We found that the therapeutic effect of RSG against tPA‐induced HT and BBB disruption was abolished in the presence of GW9662, suggesting a critical role of PPAR‐γ activation in the RSG‐afforded protection in tPA‐induced HT after stroke. The gene discussed is PPARG; the disease is hematocrit.